Anton Glieder as founder and CEO had the wish that patented research results would not be lost. And the vision was to make them marketable and scalable for a wide range of applications in the pharmaceutical, food, animal feed and medical industries. No sooner said than done. Today, the resulting products range from bioadhesives to basic ingredients for meat substitutes, molecular tools for insulin production to biomaterials for tissue building blocks for medical implants, to name just a few possible applications.

 

 

The future of the young biotech company looks bright - strong market growth and a multitude of opportunities for product innovation. At this point, it is crucial to make groundbreaking decisions with the right strategy and a suitable, future-oriented structure.

 

 

i2m has accompanied this process of strategy development. The basis is the roadmapping method of the Institute for Manufacturing of Cambridge University (UK). Equipped with this scientifically based method, which has been tested and continuously developed with leading companies worldwide, and a broad knowledge of experience in the handling of complex innovation projects, i2m guided Anton Glieder and his highly motivated team to the goal of identifying the future key innovations for the company and putting them into practice. In a series of workshops customised by i2m with the team involved, the formulas for success in the future were developed in a consensual process.

 

 

In cooperation with i2m, Bisy has managed to

• develop a unified strategic picture for the future of the company

• launched the implementation of key innovation projects

• empowered the management team to lead the company into a successful future in a focused way